BRPI0413283A - derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2 - Google Patents

derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2

Info

Publication number
BRPI0413283A
BRPI0413283A BRPI0413283-1A BRPI0413283A BRPI0413283A BR PI0413283 A BRPI0413283 A BR PI0413283A BR PI0413283 A BRPI0413283 A BR PI0413283A BR PI0413283 A BRPI0413283 A BR PI0413283A
Authority
BR
Brazil
Prior art keywords
cyclohexane derivatives
thio
receptor antagonists
dopamine
carbamoyl
Prior art date
Application number
BRPI0413283-1A
Other languages
English (en)
Inventor
Eva Againe Csongor
Janos Galambos
Katalin Nogradi
Istvan Vago
Bela Kiss
Istvan Laszlovszky
Judit Lasky
Katalin Saghy
Istvan Gyertyan
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of BRPI0413283A publication Critical patent/BRPI0413283A/pt
Publication of BRPI0413283B8 publication Critical patent/BRPI0413283B8/pt
Publication of BRPI0413283B1 publication Critical patent/BRPI0413283B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADOS DE (TIO) CARBAMOIL-CICLOHEXANO COMO ANTAGONISTAS DE RECEPTOR D~ 3~/D~ 2~". A presente invenção se relaciona aos novos ligantes de preferência dos subtipos de receptor D~ 3~ e D~ 2~ de dopamina de fórmula (I) : onde R~ 1~ e R~ 2~ representam independentemente um substituinte selecionado de hidrogênio, alquil, aril, cicloalquil, aroil, ou R~ 1~ e R~ 2~ podem formar um anel heterocíclico com o átomo de nitrogênio adjacente; X representa um átomo de oxigênio ou enxofre; n é um número inteiro de 1 a 2, e/ou isómeros e/ou estereoisómeros e/ou diastereómeros geométricos e/ou sais e/ou hidratos e/ou solvatos desses, aos processos para produção dos mesmos, às composições farmacêuticas que contêm os mesmos e para seu uso na terapia e/ou prevenção de uma condição que requer a modulação de receptores de dopamina.
BRPI0413283-1A 2003-08-04 2004-05-21 Composto derivado de (tio)carbamoil-ciclohexano, seu processo de preparação, amina, composição farmacêutica e uso do composto BRPI0413283B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0302451A HU227534B1 (en) 2003-08-04 2003-08-04 (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HUP0302451 2003-08-04
PCT/HU2004/000056 WO2005012266A1 (en) 2003-08-04 2004-05-21 (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0413283A true BRPI0413283A (pt) 2006-10-10
BRPI0413283B8 BRPI0413283B8 (pt) 2021-10-05
BRPI0413283B1 BRPI0413283B1 (pt) 2021-10-05

Family

ID=89981557

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413283-1A BRPI0413283B1 (pt) 2003-08-04 2004-05-21 Composto derivado de (tio)carbamoil-ciclohexano, seu processo de preparação, amina, composição farmacêutica e uso do composto

Country Status (37)

Country Link
US (2) US7737142B2 (pt)
EP (1) EP1663996B1 (pt)
JP (1) JP3999806B2 (pt)
KR (1) KR100870284B1 (pt)
CN (1) CN1829703B (pt)
AU (1) AU2004261490B2 (pt)
BE (1) BE2017C045I2 (pt)
BR (1) BRPI0413283B1 (pt)
CA (1) CA2532818C (pt)
CY (2) CY1113099T1 (pt)
DK (1) DK1663996T3 (pt)
EA (1) EA009022B1 (pt)
ES (1) ES2389840T3 (pt)
FR (1) FR17C0008I1 (pt)
HK (1) HK1093494A1 (pt)
HR (1) HRP20120715T1 (pt)
HU (2) HU227534B1 (pt)
IL (1) IL172746A (pt)
IS (1) IS2905B (pt)
LT (1) LTC1663996I2 (pt)
LU (1) LUC00039I2 (pt)
MA (1) MA28024A1 (pt)
ME (1) ME00564B (pt)
MX (1) MXPA06001033A (pt)
MY (1) MY142760A (pt)
NL (1) NL300913I2 (pt)
NO (2) NO334973B1 (pt)
NZ (1) NZ544999A (pt)
PL (1) PL1663996T3 (pt)
PT (1) PT1663996E (pt)
RS (1) RS52771B (pt)
SI (1) SI1663996T1 (pt)
TN (1) TNSN05328A1 (pt)
TW (1) TWI327141B (pt)
UA (1) UA84022C2 (pt)
WO (1) WO2005012266A1 (pt)
ZA (1) ZA200601026B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
JP5087631B2 (ja) * 2006-10-31 2012-12-05 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ２ａ及びｄ３受容体のデュアルモジュレーターのエーテル誘導体
HUP0700269A2 (en) * 2007-04-11 2009-04-28 Richter Gedeon Nyrt Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
PL2185155T3 (pl) * 2007-08-03 2018-03-30 Richter Gedeon Nyrt. Kompozycje farmaceutyczne zawierające ligandy receptora dopaminy i sposoby leczenia z zastosowaniem ligandów receptora dopaminy
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) * 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) * 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
HUP0900790A2 (en) 2009-12-17 2011-09-28 Richter Gedeon Nyrt A new process for the preparation of piperazine and their hydrochloric salts
CN103130737B (zh) * 2011-12-05 2015-12-02 江苏恒谊药业有限公司 环己烷胺类化合物及其作为抗精神分裂症药物的应用
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
DK2906221T3 (da) 2012-10-11 2019-07-22 Southern Res Inst Urinstof og amidderivater af aminoalkylpiperaziner og anvendelse deraf
HU231227B1 (hu) 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
ITMI20131693A1 (it) 2013-10-14 2015-04-15 Chemo Res S L Derivati della 1,4-cicloesilammina e loro preparazione
CN105085346B (zh) * 2015-08-14 2017-03-29 天津小新医药科技有限公司 含胺基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105085345B (zh) * 2015-08-14 2016-09-14 天津小新医药科技有限公司 含硝基的l-薄荷醇类p2y12受体拮抗剂及其用途
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN106543039A (zh) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 一种用于制备卡利拉嗪的化合物及其制备方法
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
CN105330616B (zh) * 2015-12-09 2017-09-26 苏州明锐医药科技有限公司 卡利拉嗪的制备方法
EP3231418A1 (en) 2016-04-14 2017-10-18 Richter Gedeon Nyrt. Granule formulation for oral administration
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN107793350B (zh) * 2016-09-05 2021-06-04 上海医药工业研究院 芳乙基哌啶基衍生物及其治疗精神分裂症的应用
HUP1700253A1 (hu) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
WO2018229794A1 (en) 2017-06-13 2018-12-20 Cipla Limited Amorphous form of cariprazine
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
JPWO2019146739A1 (ja) 2018-01-26 2021-01-07 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する縮環化合物
CN108586389B (zh) * 2018-06-29 2020-06-12 成都福柯斯医药技术有限公司 一种合成卡利拉嗪的方法
CN110872262A (zh) 2018-08-29 2020-03-10 上海科胜药物研发有限公司 一种卡利拉嗪的合成方法
CN110872270A (zh) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 一种环己烷衍生物的盐
CN111320594A (zh) * 2018-12-13 2020-06-23 江苏恩华药业股份有限公司 一种卡利拉嗪杂质及其制备工艺和用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
CN110372557B (zh) * 2019-08-06 2021-05-18 上海勋和医药科技有限公司 环己烷胺类d3/d2受体部分激动剂
AU2020376090A1 (en) 2019-10-29 2022-04-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
US20230002364A1 (en) 2019-11-05 2023-01-05 Shanghai Hansoh Biomedical Co., Ltd. Benzothiophene derivative regulator, preparation method therefor and use thereof
HUP2100108A1 (hu) 2021-03-12 2022-09-28 Richter Gedeon Nyrt Eljárás és berendezés gyógyászatilag alkalmazható piperazin származékok folyamatos áramú, áramlásos konszekutív redukálással történõ elõállítására
CA3216904A1 (en) 2021-04-28 2022-11-03 Jinyao CHEN Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
IL311268A (en) 2021-09-15 2024-05-01 Richter Gedeon Nyrt A process for the production of (1R, 4R)-4-disubstituted cyclohexane-1-amines
HUP2200312A1 (hu) 2022-08-05 2024-02-28 Richter Gedeon Nyrt Kariprazin tartalmú szájban diszpergálódó tabletta
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011070A1 (en) 1995-09-22 1997-03-27 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
CA2326804C (en) 1998-03-31 2006-05-02 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2005012266A1 (en) 2005-02-10
IL172746A (en) 2016-02-29
HRP20120715T1 (hr) 2012-09-30
HU227534B1 (en) 2011-08-29
IS2905B (is) 2014-10-15
US20060229297A1 (en) 2006-10-12
JP3999806B2 (ja) 2007-10-31
IS8199A (is) 2005-12-22
LTPA2017027I1 (lt) 2017-09-25
FR17C0008I1 (fr) 2018-12-07
BE2017C045I2 (pt) 2023-08-09
CN1829703A (zh) 2006-09-06
NL300913I2 (nl) 2017-12-20
RS20060041A (en) 2009-11-10
EA009022B1 (ru) 2007-10-26
ZA200601026B (en) 2007-05-30
MY142760A (en) 2010-12-31
AU2004261490B2 (en) 2008-08-21
KR20060058096A (ko) 2006-05-29
US7737142B2 (en) 2010-06-15
ME00564A (en) 2011-12-20
HK1093494A1 (en) 2007-03-02
TNSN05328A1 (en) 2007-07-10
IL172746A0 (en) 2006-04-10
CY1113099T1 (el) 2016-04-13
ME00564B (me) 2011-12-20
HU0302451D0 (en) 2003-10-28
NO2017051I1 (no) 2017-10-09
HUP0302451A2 (hu) 2005-05-30
CA2532818C (en) 2009-07-14
LUC00039I1 (pt) 2017-10-16
AU2004261490A1 (en) 2005-02-10
EP1663996A1 (en) 2006-06-07
EP1663996B1 (en) 2012-06-20
JP2007501215A (ja) 2007-01-25
EA200600364A1 (ru) 2006-06-30
NO20061076L (no) 2006-03-06
PT1663996E (pt) 2012-09-24
ES2389840T3 (es) 2012-11-02
KR100870284B1 (ko) 2008-11-25
MA28024A1 (fr) 2006-07-03
CA2532818A1 (en) 2005-02-10
NZ544999A (en) 2009-07-31
BRPI0413283B8 (pt) 2021-10-05
LTC1663996I2 (lt) 2018-05-25
SI1663996T1 (sl) 2012-10-30
CY2017032I1 (el) 2018-02-14
CN1829703B (zh) 2011-06-08
US20100240640A1 (en) 2010-09-23
NO334973B1 (no) 2014-08-11
LUC00039I2 (pt) 2017-12-20
NO2017051I2 (no) 2018-11-19
TWI327141B (en) 2010-07-11
NL300913I1 (pt) 2017-11-23
TW200505874A (en) 2005-02-16
RS52771B (en) 2013-10-31
DK1663996T3 (da) 2012-10-01
MXPA06001033A (es) 2006-04-24
CY2017032I2 (el) 2018-02-14
UA84022C2 (ru) 2008-09-10
BRPI0413283B1 (pt) 2021-10-05
HUS1700044I1 (hu) 2017-11-28
PL1663996T3 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
BRPI0413283A (pt) derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2
BRPI0606895A2 (pt) novos compostos com efeito terapêutico
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
DOP2006000063A (es) Derivados de ciclopropanocarboxamida
BR0309106A (pt) Derivados de terfenila, seu preparo, as composições farmacêuticas que os contêm
BR0111019A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
ECSP066667A (es) Derivados de ciclohexano espirociclicos
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
CY1117132T1 (el) Παραγωγο θειαζολιου
IL161559A0 (en) Dibenzylamine derivatives and pharmaceutical compositions containing the same
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
BR0108894A (pt) Composição farmacêutica, compostos e processo de preparação de compostos
BR0009007A (pt) Derivados de piperidina, tetraidropiridina epiperazina; composto; composição farmacêutica;utilização e método
NO862208D0 (no) Fremgangsmaate fpr fremstilling av heterocykliske forbindelser.
RS53108B (en) AMINO-1,3,5-TRIAZINES N-REPLACED BY CHIRAL BICYCLIC RADICALS, THE PROCESS FOR THEIR PREPARATION, THEIR COMPOUNDS AND THEIR APPLICATIONS AS HERBICIDES AND PLANT GROWTH REGULATORS
HUP0402313A2 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
BRPI0508072A (pt) derivados de piperidinilalquicarbamatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
CO6251252A2 (es) Metabolitos de derivados del (tio)-carbamoil-ciclohexano
BR0111061A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptor muscarìnico a61p 21/02
BR0309748A (pt) Derivados de n-acil piperidina e composição compreendendo os mesmos
BR112019006675A2 (pt) derivado heterocíclico nitrogenado bicíclico e composição farmacêutica contendo o mesmo
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
AR037459A1 (es) Antagonistas vi del receptor ccr-3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: RICHTER GEDEON NYRT. (HU)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2648 DE 05/10/2021 QUANTO AO ENDERECO E AO NOME DO INVENTOR.